# FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-0287				
Estimated average burden					
nours per response	e 0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)												
1. Name and Address of Reporting Person * Ende Eric J			Issuer Name and Ticker or Trading Symbol     Matinas BioPharma Holdings, Inc. [MTNB]				:	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner						
(Last) (First) (Middle) C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302			3. Date of Earliest Transaction (Month/Day/Year) 03/30/2018						or (give title belo		10% Owner Other (specify b	elow)		
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)				-	6. Individual or Joint/Group Filing(Check Applicable Line)  _X_Form filed by One Reporting Person  Form filed by More than One Reporting Person						
BEDMINSTER, NJ 07921 (City) (State) (Zip)			(Zip)	Table I - Non-Derivative Securities Acqui				ired, Disposed of, or Beneficially Owned						
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	(Instr. 8)		4. Securities Acquires (A) or Disposed of (D) (Instr. 3, 4 and 5)		of	5. Amount of Securit Beneficially Owned Reported Transaction (Instr. 3 and 4)		Following	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
					Code	V	Amount	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)
Common	Stock		03/30/2018		A		11,760 (1)	A	\$ 0	11,760			D	
				erivative Securitie	es Acquire	d, Dis	sposed of,	or Bene	eficial	-		ntrol numb	er.	
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Y	3A. Deemed Execution Date (ear) any	4. te, if Transaction Code (ear) (Instr. 8)	5. Number 6. D		ate Exercisable Expiration Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number or Derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Ownersh Form of Derivativ Security: Direct (Dor Indirect)	Ownership: (Instr. 4) O)
				Code V	(A) (D)	Date Exer	cisable D	xpiration ate	Title	Amount or Number of Shares				
Repor	ting O	wners												
	Reporting	Owner Name	/ Address	Re	lationship									
	reporting	Owner Ivanie	Additos	D:	0	CC.	0.1							

Describer Occurs Name / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Ende Eric J C/O MATINAS BIOPHARMA HOLDINGS, INC. 1545 ROUTE 206 SOUTH, SUITE 302 BEDMINSTER, NJ 07921	X					

## **Signatures**

/s/ Jerome D. Jabbour, attorney-in fact for Eric J. Ende		04/02/2018
Signature of Reporting Person		Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On March 30, 2018, the Reporting Person was issued 11,760 shares of common stock par value \$.0001 per share which vest immediately upon grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

